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ABSTRACT 
Carvedilol poly(D,L)-lactide nanoparticles/microparticles were prepared. The size and morphology of the 
developed particles were optimized to study the carvedilol release profile by studying the effect of 
organic solvents and polymer amount through atomic force microscopy analysis. Spherical particles were 
obtained with a minimum size of 125 nm in the case of acetone and a maximum size of 970 nm in the 
case of dichloromethane affording microparticles formation. The interaction was confirmed by differential 
scanning calorimeter and Fourier transform infrared. The in vitro release profile of the multicompartment 
system (pure carvedilol, loaded nanoparticles and microparticles) has shown a sustained release with 
Korsmeyer–Peppas with T lag model.   
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1. Introduction 
Biodegradable polymeric particles have attracted huge interest 
in the last decades in several pharmaceutical fields especially 
in the development of effective drug delivery systems of 
hydrophobic drugs [1–5]. These particles can be utilized to 
improve the bioavailability of drugs by increasing water solu-
bility of the loaded drug, improving stability of sensitive drugs, 
and achieving extended drug effect by offering a sustained 
delivery, which consequently improve the therapeutic efficacy 
and safety of the administrated drug [6–9]. Poly(D,L)-lactide 
(PDLLA), the amorphous polymeric form of polylactide, 
is one of the most commonly used polymers. It has been 
approved by the Food and Drug Administration for medical 
and drug delivery applications. It can be hydrolyzed totally in 
the physiological fluids by the cleavage of the ester bond and 
metabolized to water and carbon dioxide through Krebs 
cycle [10,11]. Several techniques were used in order to develop 
polymeric particles by using PDLLA. Nanoprecipitation 
method developed by Fessi et al. [12] is considered the most 
commonly used one. This technique has the advantages to 
produce particles in a simple and an easy manner and the 
avoidance of the usage of highly toxic organic solvents [13,14]. 
Although this technique is widely used, various limitations exist 
such as the difficulties to obtain a narrow size distribution, and 
the effects of the solvent used and the amount of the polymer on 
the size and the size distribution of the obtained particles. 
Carvedilol, as a model of a hydrophobic drug, is an antihy-
pertensive drug that acts as a nonselective β/α1 blocking agent 
and it is commonly used to treat congestive heart failure and 
to reduce the mortality of cardiovascular problems in patients 
with post-myocardial infarction [15]. The systematic bioavail-
ability of carvedilol is about 25–35% with half-life of 6 h and 
consequently provoke poor patient compliance because of 
the multiple daily dosing [16,17]. Various attempts have been 
developed in order to improve patient compliance such as the 
controlled-release technologies [18,19]. However, polymeric 
particles have the advantage over the conventional con-
trolled-release pharmaceutical dosage forms in protecting the 
drug from the chemical and enzymatic degradation and the 
hepatic metabolism of the drug [20,21]. As an example 
none defined  
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in 2014, Varshosaz et al. [22] designed and developed lectin- 
modified poly(ethylene-co-vinyl acetate) mucoadhesive NPs 
of carvedilol by an O/W solvent evaporation method with 
low drug concentration of 37.5 wt% of polymer. To our knowl-
edge, no one has reported previously the development of mul-
tiparticulate system for controlled release of carvedilol based 
on PDLLA polymer. 
Herein, we aim to study the effect of the organic solvent 
used and the amount of the polymer on the size of the 
obtained particles and to develop novel carvedilol-loaded 
PDLLA nanoparticles/microparticles decorated with polyox-
yethylene polymer, a masking agent of phagocytoses, with a 
concise size and high loading capacity in order to obtain a 
multiparticulate drug delivery system of carvedilol with 
sustained-release behavior. Atomic force microscopy (AFM) 
has been used to determine the size, size distribution, and 
morphology of the obtained particles as AFM is considered 
a powerful tool of analysis since it is used in ambient condition 
of the sample [23–27]. 
2. Experimental 
2.1. Materials, reagents, and instrumentation 
Poly(D,L) lactide polymer (intrinsic viscosity of 0.25–0.35 dL g  1 
and molecular weight of 18,000–28,000), poly oxyethylene 
cetyl ether (POE), and polyvinyl alcohol (PVA) surfactants 
were purchased from Sigma-Aldrich (Germany). Carvedilol 
(a micronized powder with particle size 90% less than 80 µm) 
was donated from Bait Jala Pharmaceutical Company in 
Palestine. HPLC grade organic solvents were used (ethanol, 
methanol, acetone, tetrahydrofuran, acetonitrile, and dichloro-
methane). Acrodisc GF syringe filters of 200 and 1,000 nm size 
were purchased from Sigma-Aldrich, and Spectra/Por 4 dialysis 
membrane (12–14 kD MWCO, 25 mm flat width, 100 foot 
length) was purchased from Spectrum Laboratories, Inc. 
(USA). 
For the quantification of the loaded carvedilol, a calibration 
curve was constructed using a Jenway 7315 UV/Visible Spec-
trophotometer with quartz cuvettes. An FTIR Spectrometer 
(Nicolet iS5, Thermo Fisher Scientific Company, USA) was 
also used. AFM using a tapping mode-AFM system with 
WSxM software designed by Nanotec Electronica (Madrid, 
Spain) was used for image analysis. Differential scanning 
calorimeter (DSC) of TA instruments with a closed aluminum 
pan under nitrogen gas was used at a heating rate of 10°C 
min  1 over the temperature range between 25 and 400°C. 
2.2. Preparation of PDLLA particles 
Poly(D,L) lactide particles were prepared using nanoprecipita-
tion technique as shown in Scheme 1. In this procedure the 
organic phase was prepared using various quantities of PDLLA 
polymer (12.5, 25, or 50 mg) and POE (5 mg). These compo-
nents were dissolved in various quantities of organic solvents 
(acetone, tetrahydrofuran, acetonitrile, ethanol, and dichloro-
methane) according to Table 1. The organic phase was added 
drop by drop to the aqueous phase that contained 3 g of 1% 
PVA and 7 mL of Milli Q water under mild stirring. The 
formed milky emulsion was left 30 min under mild stirring. 
After that, the organic solvent was evaporated using a rotary 
Scheme 1. Schematic representation of nanoprecipitation method and its relevant chemistry.  
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evaporator. The obtained system was filtered using a 200-nm 
pore size membrane syringe filter; in the case of dichloro-
methane as solvent the particles were filtered by a 1-µm pore 
size syringe filter. Centrifugation was done at 15,000 rpm for 
10 min to precipitate the particles and wash with Milli Q water 
three times to remove residual PVA. The particles were col-
lected and solubilized in 2 mL water and left in a refrigerator 
to be lyophilized the next day. 
To optimize the conditions of the prepared PDLLA parti-
cles various formulas were prepared. The organic solvent 
and the amount of PDLLA were modified. The size, mor-
phology, and size distribution of the PDLLA particles were 
assessed using AFM technique. 
Once the conditions had been optimized, 2 mg of carvedilol 
was added to the organic phase and the same procedure was 
followed. 
2.3. Preparation of AFM samples 
The samples were deposited on a substrate (5 � 5 mm2) of 
mica and were allowed to dry at room temperature. The 
AFM images were treated with WSxM 5.0 Develop 6.5 soft-
ware [28]. The size and size distribution were determined by 
taking the average of 100 counted particles. 
2.4. Encapsulation efficiency of carvedilol 
The total amount of carvedilol that had been loaded was deter-
mined by dissolving a known amount of the obtained particle 
powder in a volume of Milli Q water and measuring the absor-
bance by spectrophotometer at kmax ¼ 240 nm using the blank 
PDLLA particles as a reference in order to eliminate their 
interference. Unloaded carvedilol was also determined after 
centrifugation of the particles at 15,000 rpm for 10 min and 
encapsulation efficiency calculated according to Eq. 1: 
Encapsulation efficiency
¼
total drug content mgð Þ   free dissolved drug mgð Þ
drug amount usedðmgÞ
ð1Þ
2.5. Differential scanning calorimetry 
Five milligram samples were accurately weighed and heated on 
a closed aluminum pan at a heating rate of 10°C min  1 over 
the temperature range between 25 and 400°C and cooled to 
room temperature in two-cycle form. 
2.6. In vitro drug release profile 
In vitro release profile for carvedilol was carried out using a 
bag dialysis membrane (cutoff 14 kDa) as described here. Five 
milligrams of carvedilol-loaded PDLLA nanoparticles (NPs) or 
microparticles (MPs) were dissolved in 5 mL of phosphate buf-
fer (pH 7.4 or 6.8) and injected inside the membrane bag by a 
syringe. After that, the dialysis bag was immersed in a 900-mL 
phosphate buffer (with pH of 7.4 or 6.8) at room or body tem-
perature (25 � 1°C; 37 � 1°C) under mild stirring at a rate of 
50 rpm as recommended by the FDA dissolution procedure 
for carvedilol tablet [29]. At scheduled time intervals, 5 mL 
of the release medium was removed and replaced with the 
same volume of fresh buffer and then analyzed by a UV spec-
trophotometer to calculate the amount of drug released at 
kmax ¼ 240 nm as: 
% drug release
¼
amount of drug released at time t minð Þ
total amount of nanocapsulated drug ðmgÞ
� 100%
ð2Þ
In addition, in vitro release profile of a mixture of pure 
carvedilol, carvedilol-loaded NPs, and carvedilol-loaded MPs 
(1:1:1) was constructed at body temperature and at two pH 
values (6.8 and 7.4). 
2.7. Drug release kinetics 
Seven kinetic models were used to analyze the data of 
carvedilol release from the obtained carvedilol-loaded PDLLA 
particles and were computed using DDsolver, which is an 
Excel-plugin module [30]. The used models were zero order, 
zero order with T lag, first order, first order with T lag, 
Korsemeyer–Peppas, Korsemeyer–Peppas with T lag, and 
Higuchi model. The linear regression (R2) and Akaike 
information criterion (AIC) were calculated [31–37]. 
3. Results and discussion 
The particles were prepared using a nanoprecipitation tech-
nique, and different parameters were controlled and varied 
in order to find the optimum conditions to obtain the best 
particles. Moreover, the particles were covered by a layer of 
polyethylene oxide, which acts as a protective mask against 
opsonization of the drug transporter and subsequently 
prevents phagocytosis by the mononuclear phagocyte system 
[38,39]. 
Table 1. Formulas of PDLLA nanoparticles preparation. 
Materials 
Formulas and quantities 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10  
PDLLA (mg)  50  50  50  50  50  50  50  50  25  12.5 
PVA 1% (g)  3  3  3  3  3  3  3  3  3  3 
Polyoxyethylene cetyl ether (mg)  5  5  5  5  5  5  5  5  5  5 
Acetone (mL)  5  0  0  0  2.5  2.5  0  0  5  5 
Tetrahydrofuran (mL)  0  5  0  0  2.5  0  2.5  0  0  0 
Acetonitrile (mL)  0  0  5  0  0  2.5  2.5  0  0  0 
Ethanol (mL)  0  0  0  5  0  0  0  0  0  0 
Dichloromethane (mL)  0  0  0  0  0  0  0  5  0  0 
Milli Q water (mL)  7  7  7  7  7  7  7  7  7  7 
PDLLA, poly(D,L) lactide; PVA, polyvinyl alcohol.   
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In this study two formulation parameters were optimized 
and studied because they had a major impact on the size, 
shape, and size distribution of the particles using the PDLLA 
(Mwt ¼ 18,000–28,000) as the targeted polymer in the whole 
study. These two parameters were the quantity of the 
polymer and the type of organic solvent. Accordingly, the 
temperature and the stirring speed were kept constant (room 
temperature and mild stirring at 300 rpm). 
3.1. Effect of the organic solvent 
Four different water-miscible organic solvents (acetone, etha-
nol, tetrahydrofuran, and acetonitrile) were used in order to 
optimize the conditions to give the desired particle size, shape, 
and size distribution. Mixtures of these solvents in a 1:1 ratio 
(acetone:tetrahydrofuran, acetone:acetonitrile, and tetrahydro-
furan:acetonitrile) were also tested for the same purpose. To 
evaluate the effect of water immiscibility on the particles, 
dichloromethane was selected as the organic solvent according 
to Sawalha et al. [40]. Eight formulas were prepared and ana-
lyzed by AFM in order to determine the size, morphology, and 
size distribution of the obtained particles (Table 1). An excess 
amount (50 mg) of PDLLA was selected in order to minimize 
the effects of polymer concentrations on the particles. 
All solvents provided the same spherical shape. However, a 
difference in particle size was observed (Table 2). In fact, all 
miscible organic solvents produce particles in the nano size 
and acetone alone produced the smallest polymeric nanoparti-
cles (NPs) with the narrowest size distribution, as can be 
observed in Figure 1 and Table 2. 
Ethanol gave the largest nanoparticles when compared 
with the other miscible solvents (tetrahydrofuran, acetoni-
trile, and mixtures) (Figures S1–S6, Table 2). Mixtures of 
the miscible organic solvents made a difference in terms of 
the particle size and size distribution. The acetonitrile and 
tetrahydrofuran mixture gave a larger nanoparticle size com-
pared with the other two mixtures (Figures S2–S6, Table 2). 
This indicates that a mixture of solvents decreases the surface 
tension with the aqueous phase. The addition of acetone to 
another organic solvent positively affected the interfacial ten-
sion of the system, because it gave smaller PDLLA nanopar-
ticles when compared to the other solvent mixtures (Table 2). 
This is in accordance with the published studies showing that 
the addition of a water-miscible solvent decreases the interfa-
cial tension, and so the removal rate from the particle 
increases, which solidifies the particles much more quickly 
and, therefore, decreases the particle size [40,41]. Indeed, 
organic–aqueous phase interactions play a major role during 
the diffusion process in the formation of particles. On the 
other hand, the water-immiscible solvent dichloromethane 
produced PDLLA microparticles (MPs) instead of nanoparti-
cles (Figure 2, Table 2). This can be explained because the 
removal of dichloromethane from the aqueous phase was 
slow because of the low water miscibility, which affected 
the coacervation of the polymer. In fact, this process took 
much more time, which allowed the liquid to aggregate 
and form larger particles. This can be explained as dichloro-
methane is a water-immiscible solvent, so its removal and 
evaporation rate would be slow and so the solidification 
and precipitation processes would take longer time. This 
allows the remained liquid droplets to aggregate and coalesce, 
leading to larger and wider distributed droplets. However, in 
the case of water-miscible solvents, especially acetone, the 
evaporation rate is quicker because of the decrease of the 
interfacial tension of the droplets. This may lead to a faster 
precipitation and solidification of the polymer, which may 
result in a smaller size and better size distribution of the 
obtained particles as has been previously shown by Sawalha 
et al. [40] who prepared microparticles using dichloro-
methane in the organic phase. The size of these particles 
decreased upon the addition of a miscible solvent like 
ethanol. 
Table 2. Average size and size distribution of the different formulas. 
Formula Average size (nm) Size distribution (nm)  
F1 160  150–170 
F2 260  200–300 
F3 400  340–440 
F4 480  400–500 
F5 190  180–210 
F6 230  210–270 
F7 240  200–250 
F8 970  950–1,100 
F9 100  90–120 
F10 125  120–140   
Figure 1. (a) AFM image of PDLLA nanoparticles (acetone as the solvent); (b) histogram obtained from AFM analysis.  
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3.2. Effect of the amount of the polymer 
Once the most suitable solvent was determined, the effect of 
the amount of the polymer on particle size, shape, and size dis-
tribution was assessed. All other parameters were fixed and 
acetone was used. For this purpose, three different factorial 
amounts of PDLLA were studied (12.5, 25, and 50 mg). The 
use of 50 mg of PDLLA gave the largest particle size (Figure 1, 
Table 2). When 12.5 mg of PDLLA was used, the smallest and 
narrowest particle size was obtained; an average size of 100 nm 
and a size distribution between 90 and 120 nm was observed 
(Figure 3, Table 2), while 25 mg of PDLLA gave an average size 
of 125 nm and a size distribution of 120–140 nm (Figure S7, 
Table 2). At all PDLLA levels, a spherical shape was obtained. 
However, using less than 12.5 mg of the polymer was insuf-
ficient to form nanoparticles with proper shape. Therefore, 
the optimum amount of the polymer was 12.5 mg. 
It was observed that any increase in the polymer amount 
increased the average particle size. This effect can occur for 
two reasons: (1) an increase in the polymer chain per volume 
ratio, i.e., more polymer chain interactions and therefore more 
polymer aggregates will diffuse into the aqueous phase and 
thus form larger particles. On the other hand, (2) an increase 
in polymer concentration will affect the viscosity of the 
organic phase; a higher viscosity will in turn hold back the 
shear forces of the emulsion, as has been discussed by other 
researchers [42,43]. 
Therefore, the optimum conditions in the preparation of 
PDLLA nanoparticles are 12.5 mg of the PDLLA amount 
and using acetone as an organic solvent. However, PDLLA 
microparticles have been obtained in the case of using dichlor-
omethane as an organic solvent. 
3.3. Carvedilol-loaded PDLLA nanoparticles 
and microparticles 
Once the method of preparation had been optimized, both 
PDLLA nanoparticles and microparticles were loaded with 
carvedilol. The morphology, size, and size distribution were 
evaluated using AFM. According to AFM analysis, mainte-
nance of the spherical shape was observed, while the average 
size of both drug-loaded nanoparticles and microparticles 
increased. In fact, the average size of nanoparticles and micro-
particles was increased up to 30 and 23%, respectively. This 
increase may indicate the successful encapsulation of carvedi-
lol inside the particles (Figures S8 and S9). The loading 
capacity of PDLLA nanoparticles and microparticles was esti-
mated using a UV spectrophotometer. A calibration curve of 
carvedilol at kmax ¼ 240 nm was established in order to mea-
sure the carvedilol concentration that had been loaded inside 
the particles. 
The absorbance of PDLLA nanoparticles and microparticles 
was measured at 240 nm, and the encapsulation efficacy was 
calculated according to Eq. 1. Both nanoparticles and 
Figure 2. (a) AFM image of PDLLA microparticles (dichloromethane as the solvent); (b) histogram obtained from AFM analysis.  
Figure 3. (a) AFM image of PDLLA nanoparticles (with 12.5 mg quantity of PDLLA); (b) histogram obtained from AFM analysis.  
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microparticles showed comparable loading efficiency with 57 
and 55% loading capacity, respectively. 
3.4. Differential scanning calorimetry analysis 
Differential scanning calorimetry was conducted to confirm 
the interaction between the carvedilol and PDLLA polymer 
in both the microparticle and nanoparticle formulations and 
to study the thermal stability of the interaction. As can be 
observed in Figure 4, the DSC spectrum of the pure carvedilol 
displayed a sharp melting peak at 120°C (Figure 4a). Mean-
while, an endothermic peak at 55°C was observed in 
Figure 4b, which corresponds to the Tg of the amorphous 
PDLLA polymer. Interestingly, these two endothermic peaks 
were observed in the DSC spectra of both the carvedilol- 
loaded nanoparticles and those at 57 and 119°C in the case 
of the microparticles (Figure 4c) and at 56.5 and 117°C in 
the case of the nanoparticles (Figure 4d). This confirms the 
interaction between the carvedilol and PDLLA as the two 
characteristic peaks were observed with a slight shifting from 
the pure drug or PDLLA because of the interaction. A decrease 
in the temperature of the loaded carvedilol in both formula-
tions is due to its encapsulation, and the observed peak corre-
sponds to the carvedilol adsorbed in the surface of the 
particles, which is related to the immediate release of the drug 
as seen in the in vitro release section. 
3.5. Fourier transform infrared analysis 
In the spectrum of pure carvedilol, the observed peak at 
3,340 cm  1 is assigned to the O–H or N–H stretching 
vibration of carvedilol (Figure 5a). In the spectra of carvedilol- 
loaded PDLLA nanoparticles various peaks appeared 
(Figure 5b). The peak at 2,904 cm  1 confirms the stretching 
C–H of the CH3 and CH2 of PDLLA polymer and the peak 
at 1,741 cm  1 corresponds to the stretching vibration of the 
carbonyl group on ester. More interestingly, intermolecular 
hydrogen bonding causes the broadness of FTIR peaks, as 
can be perfectly observed in the spectrum of the carvedilol- 
loaded nanoparticles at 3,341 and 1,741 cm  1, which confirms 
the hydrogen bond formation between carvedilol and PDLLA 
polymer. 
3.6. In vitro release study 
In vitro study was conducted at two different temperatures 
(25 and at 37°C) and using two different release media, pH 
6.8 and 7.4, and using dialysis membrane bags. 
Despite the temperature and pH changes, both carvedilol- 
loaded PDLLA nanoparticles and microparticles showed 
sustained-release behavior when compared to the carvedilol 
pure drug (Figure 6). In all cases, almost all the loaded quan-
tity of carvedilol was released and normalized to the release 
profile of the pure carvedilol. However, carvedilol release from 
microparticles was slower than that from nanoparticles. 
Loaded microparticles showed complete release (97%) within 
48 h while nanoparticles released carvedilol (98%) within 
24 h (Figure 6). 
This difference in drug release between loaded nanoparti-
cles and microparticles was expected because nanoparticles 
have a higher total specific surface area than microparticles. 
Figure 4. DSC spectra of carvedilol-loaded nanoparticles and microparticles. (a) 
Pure carvedilol, (b) PDLLA, (c) carvedilol-loaded microparticles, (d) carvedilol- 
loaded nanoparticles.  
Figure 5. FTIR spectra of carvedilol-loaded PDLLA nanoparticles. (a) Pure 
carvedilol, (b) carvedilol-loaded PDLLA nanoparticles.  
Figure 6. Percentage release of carvedilol at two different temperatures using 
phosphate buffer (pH 6.8) from (a) carvedilol-loaded PDLLA NPs (average size 
130 nm) and (b) carvedilol-loaded PDLLA MPs (average size 1.2 μm). All experi-
ments were conducted in triplicate.  
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In fact, the larger surface area-to-volume ratio consequently 
increases the degradation of the polymer, which results in 
release of the loaded drug [44,45]. 
Regarding the effect of temperature on the release of carve-
dilol, greater drug release was observed at body temperature 
than at room temperature. The effect of temperature on drug 
release was also maintained despite the pH of the buffer 
(Figures 6 and 7). This is due to higher permeability of the 
polymer membrane at body temperature than at room tem-
perature, as was reported by Zhang and Wu [46]. 
Regarding the effect of pH on the release pattern of carve-
dilol, a decrease in the rate of drug release was observed when 
the pH was changed from pH 6.8 to 7.4 (Figures 6 and 7). This 
pH-dependent release is due to the kinetic of hydrolysis of 
PDLLA that has been reported to be pH dependent [47]. 
These findings suggest that a mixture of these products 
could result in a sustained-release formulation with an 
immediate release of the pure carvedilol. Accordingly, the 
release pattern of carvedilol from a mixture of the pure drug, 
and loaded nanoparticles and microparticles with a compo-
sition ratio of 1:1:1 was evaluated at body temperature using 
the above phosphate buffers (Figure 8). 
Analysis of release profile can provide important infor-
mation regarding the mechanisms involved in the release of 
carvedilol from nanoparticles and microparticles. In fact, 
several release mechanisms were suggested. These include 
desorption of the drug from the surface of the polymeric 
matrix, diffusion through the pores or wall of the matrix, dis-
integration of the particles with subsequent release, and dissol-
ution and erosion of the matrix or the polymeric wall [48,49]. 
The release profiles were assessed using different kinetic mod-
els in order to find the best sustained-release model to fit the 
data. Model selection was based on the measure of fit of linear 
regression (R2) and the value of AIC, a measure of goodness of 
fit based on maximum plausibility. For a given data set, the 
most suitable model should show the lowest AIC and R2 close 
to 1. As can be seen in Table 3, the best-fit linear regression 
line (0.972) and the lowest AIC (143.4211) for carvedilol 
release at body temperature and pH 6.8 was observed using 
Korsemeyer–Peppas with T lag model. Same results were 
observed at body temperature and pH 7.4 with R2 and AIC 
equal to 0.971 and 142.76, respectively. 
These findings are in accordance with the literature, 
because the selected model should demonstrate similarity 
between observed and predicted release [50]. In fact, 
Korsemeyer–Peppas with T lag model is often used to describe 
the drug release behavior from polymeric systems when the 
mechanism of drug release is not well known or when more 
than one kind of release mechanism is involved [51,52]. 
In fact, the mechanism involved is diffusion when the 
release exponent (n) is equal to 0.43. When the value of n is 
in the range 0.43 < n < 0.85, the suggested release is an anom-
alous transport that does not obey Fick’s Law. Values of n less 
than 0.43 indicates a porous system in which transport occurs 
by a combination of diffusion through the polymeric matrix 
and diffusion through the pores. In our study the calculated 
n value was less than 0.43. This indicates a transport mech-
anism of carvedilol by a combination of diffusion through 
the polymeric matrix and diffusion through the pores. 
These results open the door toward a novel carvedilol sus-
tained-release formulation for both oral and parenteral routes. 
In fact, the release profile at pH 6.8 simulates a sustained- 
Figure 7. Percentage release of carvedilol at two different temperatures using 
phosphate buffer (pH 7.4) from (a) carvedilol-loaded PDLLA NPs (average 
size 130 nm) and (b) carvedilol-loaded PDLLA MPs (average size 1.2 μm). All 
experiments were conducted in triplicate.  
Figure 8. (a) Percentage release of carvedilol from a mixture of carvedilol powder, PDLLA loaded nanoparticles, and microparticles at pH 6.8 and at body temperature. 
(b) Percentage release of carvedilol from a mixture of carvedilol powder, PDLLA loaded nanoparticles, and microparticles at pH 7.4 and at body temperature. All 
experiments were conducted in triplicate.  
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release pattern for the production of capsules or tablets that 
contain multiunit systems composed of pure carvedilol pow-
der, and loaded nanoparticles and microparticles. This would 
release the drug at defined time intervals where carvedilol 
powder gives the initial dose while loaded nanoparticles and 
microparticles give the maintenance doses. This type of mul-
tiple unit system has received increasing interest because it 
has great advantages over single-unit systems. In fact, carvedi-
lol sustained-release capsules are available as a single-unit 
system; these units show some disadvantages including 
regarding the safety and efficacy of the dosage form [53]. 
These disadvantages could be overcome by the use of the 
above-described multiple unit system. 
Regarding parenteral sustained-release systems, the release 
pattern of carvedilol and loaded nanoparticles and microparti-
cles at pH 7.4 and at 37°C showed an ideal controlled-release 
profile that was fit to the Korsmeyer–Peppas with T lag model 
because R2 was also close to 1 and the AIC was the lowest 
among all models, as can be seen in Table 3. 
According to these findings, our mixture could be 
produced as a powder for injection. This formulation will have 
a pH close to that of the blood. In fact, this would be of great 
interest in this field, especially for carvedilol, because it is not 
available as an injection because of its insolubility. Moreover, 
this system could be used to develop and formulate sustained- 
release systems as injectable preparations and oral solid dosage 
forms such as tablets and capsules. 
4. Conclusion 
The production of PDLLA particles with high encapsulation 
efficiency for carvedilol is possible using the nanoprecipitation 
technique. The smallest and narrowest size distribution of 
PDLLA nanoparticles was obtained when acetone was used 
as the organic solvent and 12.5 mg of PDLLA polymer was 
used and PDLLA microparticles was obtained with dichloro-
methane when used as solvent. PDLLA nanoparticles and 
microparticles improved carvedilol solubility and dissolution 
with a loading capacity of 57 and 55%, respectively. DSC 
and FTIR experiments confirm the encapsulation and the 
interaction between the carvedilol and the developed PDLLA 
nanoparticles and microparticles. In vitro release showed sus-
tained-release behavior for many hours at room and body 
temperature at two different pH levels (6.8 and 7.4). Carvedilol 
release was slower at room temperature and at pH 6.8. The 
Korsmeyer–Peppas with T lag model was the best one to 
explain the sustained-release behaviour. This work could drive 
further attempts to prepare a novel injected nanosuspension of 
carvedilol and to solve many associated problems. 
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